Asset Details
Do you wish to reserve the book?
Therapeutic treatment of hepatitis E virus infection in pigs with a neutralizing monoclonal antibody
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Therapeutic treatment of hepatitis E virus infection in pigs with a neutralizing monoclonal antibody
Do you wish to request the book?
Therapeutic treatment of hepatitis E virus infection in pigs with a neutralizing monoclonal antibody
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Therapeutic treatment of hepatitis E virus infection in pigs with a neutralizing monoclonal antibody
2025
Overview
Hepatitis E virus (HEV) poses a significant risk to human health. In Europe, the majority of HEV infection are caused by the zoonotic genotype 3 (HEV-3), which can cause chronic hepatitis E in immunocompromised patients and those with pre-existing liver disease, and may eventually develop into fatal liver cirrhosis. In this study, we examined the effectiveness of a monoclonal antibody (MAb) treatment strategy using a well established HEV-3 pig model with intravenous infection. For this purpose, nine MAbs raised against the viral capsid protein were generated and the neutralizing activities were compared using in vitro assays. The antibody with the highest neutralizing activity, MAb 5F6A1, was selected for an in vivo study in pigs infected with HEV-3. Following the initial infection of pigs with HEV-3, MAb 5F6A1 was administered intravenously one and seven days post-infection. The results suggest MAb 5F6A1 significantly reduced viremia and virus shedding in pigs infected with HEV-3. This study provides significant insight into the dynamics of HEV infection in pigs and highlights the efficacy of MAb based therapy as an option for treating HEV in porcine hosts and, potentially, humans.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 692/308
/ 692/699
/ Animals
/ Antibodies, Monoclonal - immunology
/ Antibodies, Monoclonal - pharmacology
/ Antibodies, Monoclonal - therapeutic use
/ Antibodies, Neutralizing - immunology
/ Antibodies, Neutralizing - pharmacology
/ Antibodies, Neutralizing - therapeutic use
/ Antibodies, Viral - immunology
/ Capsid Proteins - immunology
/ Hepatitis E virus - drug effects
/ Hepatitis E virus - immunology
/ Hogs
/ Humanities and Social Sciences
/ Science
/ Swine
/ Swine Diseases - drug therapy
/ Therapy
/ Viremia
/ Virus Shedding - drug effects
/ Viruses
